Role of Container Type in Stability Testing

During ICH stability studies, the container becomes the product’s primary defense against environmental stressors such as heat, humidity, light, and oxygen. Regulatory guidelines require that stability data be generated using the actual market-intended container closure system (CCS). Thus, choosing the wrong container can invalidate the stability results altogether.

Refer to ICH guidelines for container-specific stability recommendations.

Common Container Types in Pharmaceutical Packaging

Let’s look at the common container types and their respective pros and cons in the context of stability:

• Glass Vials (Type I): Highly inert and impermeable, ideal for injectables and sensitive APIs.
• Plastic Bottles (HDPE, PET): Common for oral liquids and solids, but more permeable to moisture and gases.
• Blister Packs (PVC, PVDC, Aclar): Great for unit-dose formats, require evaluation for delamination and seal integrity.
• Ampoules: Hermetically sealed glass, excellent for light and oxygen-sensitive solutions.
• Sachets and Pouches: Used for powders and granules, but prone to puncture and moisture ingress.

Key Factors Affected by Container Type

The choice of container influences several critical stability outcomes:

1. Assay and Degradation: Some plastic containers can adsorb or leach chemicals, altering API levels.
2. Moisture Uptake: Non-glass containers may allow water ingress, accelerating hydrolysis.
3. Oxygen Permeation: HDPE bottles and some blister films may not provide adequate oxygen barriers.
4. Light Protection: Amber glass offers better protection than transparent polymers.
5. Migration of Additives: Plasticizers and stabilizers may migrate into the drug product.

These effects must be simulated in forced degradation and long-term studies to assess real-world performance.

Comparative Study Example: Glass vs Plastic for Oral Solutions

In a comparative study of a vitamin C oral solution, batches stored in Type I glass showed less than 1% assay loss at 3 months under 40°C/75% RH. Meanwhile, the same solution in PET bottles degraded by nearly 5%, attributed to oxygen ingress through the polymer. This illustrates how material permeability influences stability—even when both containers meet pharmacopeial standards.

Checklist for Evaluating Container Type During Development

• Chemical compatibility with formulation (avoid reactivity)
• Water vapor transmission rate (WVTR)
• Oxygen transmission rate (OTR)
• Resistance to light, breakage, and stress
• Closure system compatibility and sealing integrity
• Suitability for sterilization (if required)
• Global regulatory acceptability

These parameters should be evaluated under simulated transport and storage conditions before final selection.

Regulatory Expectations for Container Selection

Regulators like the USFDA and EMA mandate that stability data must reflect the final market presentation. If a different container is used during R&D, bridging studies or justifications are required in the dossier.

• Include extractables and leachables studies (USP , )
• Document justification for container choice
• Provide validation reports for sealing and integrity

These records should appear in CTD Module 3.2.P.7 of the regulatory submission.

How to Conduct Compatibility Testing Based on Container Type

Container compatibility must be tested throughout the product lifecycle. Key test methods include:

• Assay and impurity profile trending over time
• Leachables identification using LC-MS, GC-MS, ICP-MS
• Stress testing at ICH conditions (30°C/65% RH, 40°C/75% RH)
• Photostability testing per ICH Q1B
• Container Closure Integrity Testing (CCI) for sterile products

These studies must use samples stored in the exact packaging system proposed for commercial use.

Case Study: Impact of Closure Incompatibility with Plastic Vials

A company conducted a stability study for a pediatric oral antibiotic in plastic vials with screw caps. After three months at 30°C/75% RH, drug loss and microbial contamination were observed. Investigation revealed incomplete sealing due to torque loss under heat expansion. Switching to an induction-sealed cap resolved the issue and ensured container closure integrity (CCI).

This reinforces the need to validate closures in conjunction with container material and product formulation.

Tips for Selecting the Right Container Type Based on Product Class

• Injectables: Type I glass vial or ampoule + rubber stopper + aluminum seal
• Oral liquids: Amber glass or PET bottle + child-resistant cap
• Solid dose forms: PVC/PVDC blister or HDPE bottle with desiccant
• Topicals: Laminate tubes or high-barrier plastic jars
• Inhalers: Aluminum canister with metered dose valve

Always assess container impact on dosage delivery, not just physical stability.

Internal Documentation Requirements for Container Type Evaluation

Ensure the following documents are included in your packaging development file:

• Material specifications and vendor CoAs
• Summary of compatibility studies
• CCI validation reports
• Visual inspection protocols and sealing SOPs
• Photostability and migration test reports
• Packaging description in the stability protocol

Refer to Pharma SOPs for templates to document packaging qualification steps.

Link Between Container Selection and Product Shelf Life

Suboptimal containers can shorten shelf life by accelerating degradation. For instance, polyethylene containers with high moisture permeability may reduce a hygroscopic API’s shelf life from 24 to 12 months. On the contrary, blister packs with Aclar films or glass containers can extend shelf life by reducing environmental exposure.

Hence, container choice is a shelf-life defining factor—not just a packaging decision.

Conclusion

The container type used in pharmaceutical stability testing can make or break a product’s success. By evaluating chemical compatibility, moisture/oxygen permeability, mechanical protection, and regulatory compliance, pharma professionals can select the right packaging solution that ensures product integrity throughout the shelf life. Always integrate container evaluation into the early stages of formulation development and document findings rigorously.

References:

• ICH Q1A(R2) Stability Testing of New Drug Substances and Products
• ICH Q1B Photostability Testing of New Drug Substances and Products
• USP : Containers – Plastics
• USP : Assessment of Extractables
• FDA Guidance for Industry – Container Closure Systems
• EMA Guideline on Plastic Immediate Packaging Materials

Why container-closure systems matter:

Stability testing simulates how a drug product will behave over its shelf life. If the container-closure system used during testing doesn’t match the one used in the market, the results may not reflect real-world conditions.

Packaging directly impacts exposure to moisture, oxygen, and light—all of which influence chemical and physical stability. Therefore, using the final packaging system is essential for generating valid, defensible data.

Risks of mismatched testing conditions:

Testing in an alternative or interim container—such as clear vials, bulk HDPE bottles, or temporary seals—can underestimate degradation or fail to detect vulnerabilities that would arise in the actual distribution environment.

This mismatch could lead to label inaccuracies, recall risk, or regulatory rejection due to data that doesn’t match commercial conditions.

Regulatory implications of incorrect simulation:

Authorities like the FDA, EMA, and CDSCO expect that the container-closure used during stability studies mirrors the proposed commercial presentation. Deviations must be scientifically justified and rarely accepted.

Ensuring a match helps streamline regulatory approval and builds trust in the reliability of submitted shelf life claims.

Regulatory and Technical Context:

ICH Q1A(R2) requirements:

The ICH guideline explicitly mandates that stability testing be conducted using the same container-closure system proposed for marketing. This ensures the impact of packaging on product stability is fully evaluated before commercialization.

It also requires consideration of closure integrity, extractables/leachables, and the effect of packaging materials under intended storage conditions.

Container types and their stability impact:

Glass vs. plastic, screw caps vs. induction seals, blister foils vs. clear PVC—all have varying barrier properties. Each can alter moisture vapor transmission rates (MVTR), gas permeability, and light exposure.

Neglecting to use final packaging may lead to shelf life that is either overestimated or unnecessarily short, affecting product competitiveness and patient safety.

Packaging data in regulatory submissions:

Container-closure details are submitted in Module 3.2.P.7 of the CTD. Reviewers examine whether the data generated applies to the final market configuration, and if not, require bridging studies or label restrictions.

Proper testing from the start reduces back-and-forth during review and supports efficient global rollout.

Best Practices and Implementation:

Align study protocol with packaging components:

Ensure your stability protocol clearly specifies the container-closure system used for each batch. Match this to commercial packaging in terms of material, volume, and closure design.

If early batches are tested in development packaging, plan for bridging studies and outline the rationale in your protocol and submission.

Include packaging in validation and qualification plans:

Validate the packaging line and confirm it meets closure integrity requirements before stability sample preparation. Conduct visual inspections, torque tests, and leak tests to ensure packaging consistency.

Use packaging suppliers with traceable documentation and materials that meet USP, EP, or JP standards.

Account for packaging in shelf-life justification:

Include data demonstrating that the packaging supports the proposed storage conditions (e.g., light protection, moisture control). This supports shelf-life projections and labeling statements like “Store in a tightly closed container” or “Protect from light.”

Regulatory authorities may request packaging-specific stability data in post-approval variations—prepare for this in advance by maintaining a well-structured study archive.